Back

Full professor K.P.M. (Karijn) Suijkerbuijk

Full professor K.P.M. (Karijn) Suijkerbuijk

Full Professor

Show full profile

Research Output (132)

Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands

Heimovaara Joosje H., Boere I. A., de Haan Jorine, van Calsteren Kristel, Amant F., van Zuylen Lia, Lok Christine A.R., Lok C. A.R., van Zuylen L., Boere I. A., Amant F., Beerendonk C. C.M., Bellido-Casado M., Beltman J. J., Bos M. E.M.M., Duvekot J. J., Gerestein C. G., Gordijn S., de Groot C. J.M., van Grotel M., Han S. N., Heeres B. C., van den Heuvel-Eibrink M. M., Houwink A., Huitema D. R., Koken Ph W., Koppert L. B., Lugtenburg P. J., Ottevanger P. B., Painter R. C., Poortmans P. M.P., Roes E. M., van der Scheer L., Schröder C. P., Suelmann B. B.M., Suijkerbuijk K. P.M., van Tienhoven G., van Trommel N. E., Trum J. W., van der Velden J., Vriens I. J.H., Witteveen P. O., Aug 2022, In: European Journal of Cancer. 171 , p. 13-21 9 p.

Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?

Patuleia Susana I S, Moelans Cathy B, Koopman Jasmijn, van Steenhoven Julia E C, van Dalen Thijs, van der Pol Carmen C, Jager Agnes, Ausems Margreet G E M, van Diest Paul J, van der Wall Elsken, Suijkerbuijk Karijn P M 27 Jun 2022, In: BMC Cancer. 22 , p. 1-8

Hematologic malignancies following immune checkpoint inhibition for solid tumors

van Eijs Mick J.M., van der Wagen Lotte E., Mous Rogier, Leguit Roos J., van de Corput Lisette, van Lindert Anne S.R., Suelmann Britt B.M., Kamphuis Anna M., Nierkens Stefan, Suijkerbuijk Karijn P.M. 13 Jun 2022, In: Cancer Immunology, Immunotherapy. 72 , p. 249-255 7 p.

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors

Ismail Rawa K, Suijkerbuijk Karijn P M, de Boer Anthonius, van Dartel Maaike, Hilarius Doranne L, Pasmooij Anna M J, van Zeijl Michiel C T, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, de Groot Jan W B, Haanen John B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, van der Veldt Astrid A M, Vreugdenhil Art, Westgeest Hans, van den Eertwegh Alfons J, Wouters Michel W J M 6 Jun 2022, In: Melanoma Research. 32 , p. 460-468 9 p.

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma:the PRADO trial

Reijers Irene L M, Menzies Alexander M, van Akkooi Alexander C J, Versluis Judith M, van den Heuvel Noëlle M J, Saw Robyn P M, Pennington Thomas E, Kapiteijn Ellen, van der Veldt Astrid A M, Suijkerbuijk Karijn P M, Hospers Geke A P, Rozeman Elisa A, Klop Willem M C, van Houdt Winan J, Sikorska Karolina, van der Hage Jos A, Grünhagen Dirk J, Wouters Michel W, Witkamp Arjen J, Zuur Charlotte L, Lijnsvelt Judith M, Torres Acosta Alejandro, Grijpink-Ongering Lindsay G, Gonzalez Maria, Jóźwiak Katarzyna, Bierman Carolien, Shannon Kerwin F, Ch'ng Sydney, Colebatch Andrew J, Spillane Andrew J, Haanen John B A G, Rawson Robert V, van de Wiel Bart A, van de Poll-Franse Lonneke V, Scolyer Richard A, Boekhout Annelies H, Long Georgina V, Blank Christian U 5 Jun 2022, In: Nature Medicine. 28 , p. 1178-1188 11 p.

Response to immune checkpoint inhibitors in acral melanoma:A nationwide cohort study

van Not Olivier J, de Meza Melissa M, van den Eertwegh Alfons J M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, van Breeschoten Jesper, de Groot Jan-Willem B, Hospers Geke A P, Ismail Rawa K, Kapiteijn Ellen, Piersma Djura, van Rijn Roos S, Stevense-den Boer Marion A M, van der Veldt Astrid A M, Vreugdenhil Gerard, Bonenkamp Han J, Boers-Sonderen Marye J, Blokx Willeke A M, Wouters Michel W J M, Suijkerbuijk Karijn P M 4 Apr 2022, In: European Journal of Cancer. 167 , p. 70-80 11 p.

Diagnostic pitfalls after COVID-19 vaccination in melanoma and breast cancer patients:A case series

de Bock Ellen, Trumpi Kari, Suijkerbuijk Karijn P.M., Vriens Menno R., Richir Milan C. Apr 2022, In: International Journal of Surgery Case Reports. 93 , p. 1-5

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis

van Breeschoten Jesper, Wouters Michel W J M, Hilarius Doranne L, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan-Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Roos S, Suijkerbuijk Karijn P M, Blokx Willeke A M, Tije Bert-Jan J Ten, Veldt Astrid A M van der, Vreugdenhil Art, Boers-Sonderen Marye J, van den Eertwegh Alfonsus J M 7 Mar 2022, In: British Journal of Cancer. 126 1 p.

The unfavorable effects of COVID-19 on Dutch advanced melanoma care

Van Not Olivier J, van Breeschoten Jesper, van den Eertwegh Alfonsus J M, Hilarius Doranne L, De Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Ismail Rawa K, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A M, van der Veldt Astrid A M, Vreugdenhil Gerard, Boers-Sonderen Marye J, Blokx Willeke A M, Suijkerbuijk Karijn P M, Wouters Michel W J M 1 Mar 2022, In: International Journal of Cancer. 150 , p. 816-824 9 p.

Frailty and checkpoint inhibitor toxicity in older patients with melanoma

Bruijnen Cheryl P., Koldenhof José J., Verheijden Rik J., van den Bos Frederiek, Emmelot-Vonk Mariëlle H., Witteveen Petronella O., Suijkerbuijk Karijn P.M. 2022, In: Cancer. 128 , p. 2746-2752 7 p.

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not